The Cautionary Tale of PSA Testing: Comment on “Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL”

Richard M. Hoffman; Steven B. Zeliadt

doi:10.1001/archinternmed.2010.222

Invited Commentary

July 26, 2010

The Cautionary Tale of PSA Testing: Comment on “Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL”

Richard M. Hoffman, MD, MPH; Steven B. Zeliadt, PhD

Author Affiliations Article Information

Author Affiliations: Medicine Service, New Mexico VA Health Care System, and University of New Mexico School of Medicine, Albuquerque (Dr Hoffman); Health Services Research & Development Center of Excellence, VA Puget Sound Health Care System, and Department of Health Services, University of Washington, Seattle (Dr Zeliadt).

Arch Intern Med. 2010;170(14):1262-1263. doi:10.1001/archinternmed.2010.222

Full Text

The Cautionary Tale of PSA Testing: Comment on “Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL”

Others Also Liked

Special Communications

Blogs

The Cautionary Tale of PSA Testing: Comment on “Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL”

Read More About

Citation

Download citation file:

Others Also Liked

Select Your Interests